These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 29176657)

  • 1. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
    Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE
    Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.
    Hari P; Khandelwal P; Smoyer WE
    Pediatr Nephrol; 2020 Sep; 35(9):1601-1619. PubMed ID: 31302760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
    Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
    Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
    Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
    Packard CJ
    Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
    Matikainen N; Taskinen MR
    Curr Cardiol Rep; 2012 Dec; 14(6):721-31. PubMed ID: 22941588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials.
    Luo J; Huang T; Xu R; Wang X; Yang Y; Li L; Zhang X; Zhang Y; Yang R; Wang J; Yang H; Ma Y; Yang B; Wang T; Jiao L
    BMJ Open; 2022 Sep; 12(9):e061884. PubMed ID: 36691198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PCSK9 inhibitors in the management of dyslipidaemia.
    Nair T
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S44-S50. PubMed ID: 38195006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.